Abstract:
Introduction
Among all the most common cardiovascular diseases is ischemic heart disease (ICP).
At present, there is a process of "rejuvenation" of the ICC, occupying important
positions in society, which is why the given disease needs to be considered as one
with important social value. Purpose
Conduct a randomized clinical trial of the efficacy and harmlessness of
inclusion in standardized pharmacotherapy of mildronate in patients with
stable angina pectoris.Material and methods
An open randomized clinical trial was performed that included 160 patients with
CPI (117 men and 43 women) with a mean age of 59.26 ± 0.74 years. 142 patients
had stable angina pectoris from different functional classes, and 21 - unstable
angina pectoris. The control group included 30 practically healthy people. The
observation period was 6 weeks.
Results
There was a significant decrease in serum concentrations of organospecific
myocardial enzymes - CFK-MB and LDH1, which speaks of the reduction of "leakage"
of enzymes from the cytoplasm of cells following the stabilization of cardiomyocyte
membranes. A significant decrease in the plasma concentration of pyruvate was
detected, and in the mitochondria - the activation of PDH, indicating the stimulation
of the oxidative decarboxylation process of pyruvate. Also, in mitochondria a
significant activation of CS and insignificant SDH was revealed.
Conclusions
In patients with myocardial ischemia mildronate activates glycolysis, oxidative
phosphorylation and oxidative decarboxylation, stabilizes the cardiomyocyte
membrane, reduces the degree of hypoxia, restoring the level of ATP and adequate
energy intake to the myocardium.
Description:
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Disciplina de medicină internă-semiologie, Chișinău, Republica Moldova, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltare
